No CrossRef data available.
Published online by Cambridge University Press: 01 February 2011
Faculty Disclosures: Dr. Kornstein has been a consultant to Bristol-Myers Squibb, Dey Pharma, Eli Lilly, PGxhealth, Pfizer, Rexahn, and Takeda; has received research support from Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, the National Institute of Mental Health, Novartis, Otsuka, Pfizer, and Takeda; and has received book royalties from Guilford Press.Dr. Clayton has been a consultant to and/or on the advisory boards of AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, New England Research Institutes, Pfizer, PGxHealth, sanofi-aventis and Takeda; has received grant support from BioSante, Boehringer-Ingelheim, Pfizer, and Repligen Corporation; and receives royalties from Ballantine Books/Random House; Guilford Publications; the Changes in Sexual Functioning Questionnaire; and Healthcare Technology Systems, Inc.
Faculty Disclosures: Dr. Kornstein has been a consultant to Bristol-Myers Squibb, Dey Pharma, Eli Lilly, PGxhealth, Pfizer, Rexahn, and Takeda; has received research support from Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, the National Institute of Mental Health, Novartis, Otsuka, Pfizer, and Takeda; and has received book royalties from Guilford Press.Dr. Clayton has been a consultant to and/or on the advisory boards of AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, New England Research Institutes, Pfizer, PGxHealth, sanofi-aventis and Takeda; has received grant support from BioSante, Boehringer-Ingelheim, Pfizer, and Repligen Corporation; and receives royalties from Ballantine Books/Random House; Guilford Publications; the Changes in Sexual Functioning Questionnaire; and Healthcare Technology Systems, Inc.